Voriconazole as mono-therapy in orbitofrontal erosive aspergillosis without gross total resection: A case report and review of literature

•Central nervous system aspergillosis has a poor prognosis.•In immunocompetent patients treated with dual antifungal drugs and surgical resection, mortality can be as high as 66%.•A new voriconazole monotherapy can successfully treat invasive orbitofrontal aspergillosis without surgical resection. I...

Full description

Saved in:
Bibliographic Details
Published in:Clinical neurology and neurosurgery 2018-09, Vol.172, p.93-95
Main Authors: Nowak, Stephan, Bollmann, Tom, Rosenstengel, Christian, Rathmann, Eiko, Ribback, Silvia, Ewert, Ralf, Schroeder, Henry W.S.
Format: Article
Language:English
Subjects:
Antifungal agents
Antifungal Agents - therapeutic use
Aspergillosis
Aspergillosis - drug therapy
Aspergillosis - pathology
Biopsy
Brain
Case reports
Chronic obstructive pulmonary disease
CNS
Decompression
Disease
Family medical history
Fungal infections
Humans
Immunocompetence - drug effects
Lung cancer
Male
Medical prognosis
Middle Aged
Mortality
Nervous system
Optic nerve
Patients
Pneumonia
Triazoles - therapeutic use
Voriconazole
Voriconazole - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Central nervous system aspergillosis has a poor prognosis.•In immunocompetent patients treated with dual antifungal drugs and surgical resection, mortality can be as high as 66%.•A new voriconazole monotherapy can successfully treat invasive orbitofrontal aspergillosis without surgical resection. In this case report we present an immunocompetent 64-year-old patient presenting with an orbitofrontal invasive aspergillosis treated successfully with voriconazole monotherapy following biopsy and orbital decompression.
ISSN:0303-8467
1872-6968
DOI:10.1016/j.clineuro.2018.06.043